There is no universally accepted instrument to use as a validated surrogate endpoint for
overall survival in phase 2 and phase 3 multimodal rectal cancer trials using …

Rectal cancer accounts for over 35% of the worldwide colorectal cancer burden
representing a distinctive subset of cancers from those arising in the colon. Colorectal …

Background Radiosensitivity of rectal cancer is related to the radiotherapy efficacy and
prognosis of patients with rectal cancer, and the genes and molecular mechanisms related …

BACKGROUND Preoperative chemoradiotherapy (CRT) is a standard treatment modality for
locally advanced rectal cancer. However, CRT alone cannot improve overall survival …

Rectal Cancer (RC) is a complex disease that involves highly variable treatment responses.
Currently, there is a lack of reliable markers beyond TNM to deliver a personalized treatment …

Simple Summary The efficiency of (chemo-) radiotherapy for rectal cancer is not only
determined by the impact on the tumor cells themselves but also by the highly individual …

Background The gold standard treatment for locally advanced rectal cancer is total
mesorectal excision after preoperative chemoradiotherapy. Response to chemoradiotherapy …

Simple Summary There is a clinical need for predictive biomarkers that can identify patients
with rectal cancer who do not respond to preoperative neoadjuvant chemoradiotherapy. In …

Introduction Standard treatment for patients with locally advanced rectal cancer (LARC)
includes neoadjuvant chemoradiotherapy (nCRT) with fluoropyrimidines, followed by …

The clinical and pathological responses to multimodal neoadjuvant therapy in locally
advanced rectal cancers (LARCs) remain unpredictable, and robust biomarkers are still …